+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Systemic Autoinflammatory Diseases Drug Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Systemic Autoinflammatory Diseases Drug Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Systemic Autoinflammatory Diseases Drug Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6080476
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Understanding the Momentum Behind Systemic Autoinflammatory Therapeutics

The landscape of systemic autoinflammatory diseases is evolving at an unprecedented pace, fueled by breakthroughs in molecular biology and an increasing recognition of the unmet needs in patient care. Historically overshadowed by autoimmune disorders, autoinflammatory conditions have recently emerged as a critical focus for biopharma investment, spurred by novel insights into innate immune pathways. This report sets the stage by exploring the drivers behind renewed interest, including the validation of interleukin and kinase targets, the maturation of biologic platforms, and the growing impetus for personalized therapeutic regimens.

Against this backdrop, stakeholders across drug developers, regulators, and healthcare providers are navigating a complex interplay of scientific innovation, competitive dynamics, and reimbursement challenges. By distilling the latest clinical data, market trends, and regulatory shifts, our executive summary provides a cohesive orientation to the opportunities and strategic imperatives in the systemic autoinflammatory therapeutics domain. This introduction prepares the reader to delve into the transformative forces reshaping treatment paradigms.

Emerging Paradigm Shifts Driving Treatment Innovations

The treatment landscape for systemic autoinflammatory diseases is undergoing a seismic realignment, driven by an influx of next-generation inhibitors and a paradigm shift toward targeted immunomodulation. High-resolution molecular profiling has uncovered discrete patient subpopulations with distinct cytokine signatures, enabling trial designs that rapidly demonstrate proof of concept. Concurrently, digital therapeutics and remote monitoring tools are being integrated into clinical protocols to enhance adherence, optimize dosing schedules, and capture real-world evidence.

Regulatory bodies have also signaled a willingness to expedite pathways for drugs addressing rare and severe autoinflammatory syndromes, fostering public-private partnerships to accelerate development timelines. This collaborative ecosystem is further energized by strategic alliances between biotech innovators and established pharmaceutical companies, pooling expertise in biologics manufacturing and global commercialization. As a result, the industry is poised to transition from broad-spectrum immunosuppression toward precision therapies that deliver durable responses with minimized systemic toxicity.

Implications of New US Tariff Policies on Drug Accessibility

In early 2025, the U.S. government will implement revised tariff schedules affecting a range of imported pharmaceutical inputs and finished biologic products. These adjustments introduce incremental duties that have the potential to alter cost structures across the supply chain. Manufacturers reliant on overseas reagents or contract development and manufacturing organizations may see unit costs rise, necessitating a recalibration of pricing strategies. At the same time, payers and healthcare systems will face pressure to negotiate rebates or seek alternative sourcing arrangements to contain overall budget impacts.

While domestic production incentives are expected to buffer the immediate effects, companies must prepare for extended lead times as suppliers adjust capacity. This dynamic could influence launch sequencing, with priority given to high-value assets or those benefitting from patent exclusivity. Ultimately, the tariff environment underscores the need for agility in procurement, strategic inventory management, and proactive engagement with policymakers to advocate for harmonized trade policies that support innovation and patient access.

Decoding Market Composition Through Drug Class and Delivery Modes

A nuanced understanding of market composition is essential for companies to identify high-opportunity segments and allocate resources effectively. When analyzed by drug class, the market encompasses interleukin-1 inhibitors such as Anakinra, Canakinumab, and Rilonacept, interleukin-6 receptor blockade agents including Sarilumab and Tocilizumab, JAK inhibitors spanning Baricitinib, Tofacitinib, and Upadacitinib, as well as TNF inhibitors like Adalimumab, Etanercept, and Infliximab. Each class presents distinct efficacy and safety profiles, offering varied value propositions for patient subgroups.

From the perspective of mechanism of action, the distinction between interleukin-1 and interleukin-6 blockade, JAK inhibition, and tumor necrosis factor alpha inhibition informs clinical decision making and portfolio prioritization. Route of administration further stratifies the market into intravenous infusion therapies, oral treatments, and subcutaneous injections, each with implications for patient convenience, adherence, and healthcare delivery models. Distribution channels ranging from hospital pharmacies to online and retail outlets shape access paradigms, while end users-spanning clinics, home care settings, hospitals, and specialty centers-drive demand patterns and influence support services. Together, this integrated segmentation framework illuminates where targeted investment and tailored commercialization strategies will yield the greatest return.

Regional Variations Shaping Global Autoinflammatory Therapy Demand

Regional dynamics underscore the heterogeneity of systemic autoinflammatory disease markets and highlight the importance of localized strategies. In the Americas, robust reimbursement frameworks for rare disease therapies and a well-established biologics manufacturing base support rapid adoption of novel agents. However, price sensitivity and payer scrutiny require value-based contracting models to secure formulary positions.

Europe, the Middle East, and Africa present a mosaic of regulatory environments, with advanced markets leveraging centralized approval pathways and emerging regions exploring risk-sharing agreements to broaden access. The pace of uptake in these territories often hinges on the alignment between clinical guidelines and health technology assessments. In the Asia-Pacific, a combination of government-led innovation initiatives and growing domestic production capacities is driving competitive pricing, while demographic shifts fuel demand for convenient oral or self-administered therapies.

Competitive Landscape Insights from Leading Biopharma Innovators

Market leadership is increasingly contested by a mix of established pharmaceutical giants and agile biotech firms. Companies developing interleukin-1 inhibitors are focusing on subcutaneous formulations and extended-release platforms to enhance patient experience. Those driving interleukin-6 receptor blockade are advancing next-generation antibodies with improved safety margins and induction dosing protocols. In the JAK inhibitor class, strategic labeling expansions and head-to-head trials are central to capturing share, while developers of tumor necrosis factor alpha inhibitors are navigating biosimilar entry by adding value through patient support programs.

Beyond clinical differentiation, leading organizations are investing heavily in advanced analytics to refine patient segmentation, optimize supply chains, and forecast demand. Strategic collaborations and licensing agreements are proliferating, as firms seek to augment their pipelines with complementary modalities such as gene editing or RNA-based therapies. This competitive mosaic underscores the imperative for continuous innovation and agile commercialization tactics to sustain long-term growth.

Strategic Imperatives for Advancing Market Leadership

Industry leaders should prioritize a multichannel access strategy that balances hospital partnerships, specialty center outreach, and digital engagement to maximize patient reach. Integrating real-world data collection into post-launch activities will strengthen value demonstrations and support favorable reimbursement decisions. Companies operating in tariff-impacted regions must explore localized sourcing and public-private collaborations to mitigate cost pressures and maintain supply continuity.

Investment in patient education and adherence programs, particularly for self-administered therapies, will be critical to realizing the full clinical and economic benefits. Additionally, establishing alliances with technology providers can accelerate the deployment of telehealth services and remote monitoring tools that enhance patient support. Finally, proactive scenario planning for regulatory changes and competitive biosimilar threats will empower organizations to adapt swiftly and protect market share.

Rigorous Framework Underpinning Our Research Approach

Our research methodology integrates primary interviews with key opinion leaders, clinical specialists, and senior executives alongside an exhaustive review of peer-reviewed literature, regulatory filings, and company disclosures. Data triangulation ensures that insights are validated across multiple sources, while a proprietary scoring system evaluates pipeline maturity, commercial readiness, and competitive positioning.

Geographical coverage spans the Americas, Europe, Middle East, Africa, and Asia-Pacific, with segmentation analyses applied consistently to enable cross-regional comparisons. Quality control measures, including independent expert reviews and statistical sanity checks, underpin the reliability of our findings. Throughout the process, strict adherence to ethical guidelines and confidentiality protocols has been maintained.

Synthesizing Key Insights to Navigate Future Growth

Bringing together evolving science, dynamic market forces, and shifting policy landscapes, the systemic autoinflammatory disease therapeutic sector presents both formidable challenges and extraordinary opportunities. A clear understanding of segmentation dynamics, regional nuances, and competitive activities is indispensable for charting a path to sustainable growth. By aligning innovative pipelines with adaptive commercial strategies and proactive stakeholder engagement, organizations can deliver transformative therapies to patients in need while capturing lasting value.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Il-1 Inhibitors
      • Anakinra
      • Canakinumab
      • Rilonacept
    • Interleukin-6 Receptor Blockade
      • Sarilumab
      • Tocilizumab
    • Jak Inhibitors
      • Baricitinib
      • Tofacitinib
      • Upadacitinib
    • Tnf Inhibitors
      • Adalimumab
      • Etanercept
      • Infliximab
  • Mechanism Of Action
    • Interleukin-1 Blockade
    • Interleukin-6 Receptor Blockade
    • Janus Kinase Inhibition
    • Tumor Necrosis Factor Alpha Inhibition
  • Route Of Administration
    • Intravenous Infusion
    • Oral Administration
    • Subcutaneous Injection
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Clinics
    • Home Care
    • Hospitals
    • Specialty Centers
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Swedish Orphan Biovitrum AB
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • AbbVie Inc.
  • Roche Holding AG
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Novimmune SA
  • Sanofi S.A.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Systemic Autoinflammatory Diseases Drug Market, by Drug Class
8.1. Introduction
8.2. Il-1 Inhibitors
8.2.1. Anakinra
8.2.2. Canakinumab
8.2.3. Rilonacept
8.3. Interleukin-6 Receptor Blockade
8.3.1. Sarilumab
8.3.2. Tocilizumab
8.4. Jak Inhibitors
8.4.1. Baricitinib
8.4.2. Tofacitinib
8.4.3. Upadacitinib
8.5. Tnf Inhibitors
8.5.1. Adalimumab
8.5.2. Etanercept
8.5.3. Infliximab
9. Systemic Autoinflammatory Diseases Drug Market, by Mechanism Of Action
9.1. Introduction
9.2. Interleukin-1 Blockade
9.3. Interleukin-6 Receptor Blockade
9.4. Janus Kinase Inhibition
9.5. Tumor Necrosis Factor Alpha Inhibition
10. Systemic Autoinflammatory Diseases Drug Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous Infusion
10.3. Oral Administration
10.4. Subcutaneous Injection
11. Systemic Autoinflammatory Diseases Drug Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Systemic Autoinflammatory Diseases Drug Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
12.5. Specialty Centers
13. Americas Systemic Autoinflammatory Diseases Drug Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Systemic Autoinflammatory Diseases Drug Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Systemic Autoinflammatory Diseases Drug Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Swedish Orphan Biovitrum AB
16.3.3. Regeneron Pharmaceuticals, Inc.
16.3.4. Pfizer Inc.
16.3.5. AbbVie Inc.
16.3.6. Roche Holding AG
16.3.7. Amgen Inc.
16.3.8. Bristol-Myers Squibb Company
16.3.9. Novimmune SA
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET MULTI-CURRENCY
FIGURE 2. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET MULTI-LANGUAGE
FIGURE 3. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 67. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 70. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. CANADA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. MEXICO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. GERMANY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 131. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. FRANCE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. ITALY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. ITALY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 148. ITALY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 149. ITALY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. ITALY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. ITALY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 152. ITALY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. ITALY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. ITALY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SPAIN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. SPAIN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. SPAIN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 158. SPAIN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 161. SPAIN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SPAIN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. SPAIN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. DENMARK SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. DENMARK SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. DENMARK SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 194. DENMARK SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 197. DENMARK SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. DENMARK SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. DENMARK SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. QATAR SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. QATAR SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. QATAR SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 212. QATAR SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. QATAR SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. QATAR SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. QATAR SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. QATAR SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. QATAR SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FINLAND SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. FINLAND SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. FINLAND SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 221. FINLAND SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 224. FINLAND SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. FINLAND SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. FINLAND SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. EGYPT SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. EGYPT SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 247. EGYPT SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 248. EGYPT SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 251. EGYPT SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. EGYPT SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. EGYPT SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. TURKEY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. TURKEY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. TURKEY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 257. TURKEY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 260. TURKEY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. TURKEY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. TURKEY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. NORWAY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 273. NORWAY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. NORWAY SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-20

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Systemic Autoinflammatory Diseases Drug market report include:
  • Novartis AG
  • Swedish Orphan Biovitrum AB
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • AbbVie Inc.
  • Roche Holding AG
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Novimmune SA
  • Sanofi S.A.

Related Reports

Anakinra Global Market Report 2025 - Product Image

Anakinra Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Ilaris Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Ilaris Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Schnitzler Syndrome - Pipeline Insight, 2025 - Product Image

Schnitzler Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Still's Disease- Pipeline Insight, 2025 - Product Image

Still's Disease- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Bispecific Antibody Therapeutics Contract Manufacturing - Global Strategic Business Report - Product Image

Bispecific Antibody Therapeutics Contract Manufacturing - Global Strategic Business Report

  • Report
  • 382 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.